



FOR IMMEDIATE RELEASE
September 15, 2011

CONTACT: TINA L. PUGLIESE, APR
(561) 889-3575; Tina@PugliesePR.com

PRESS RELEASE

Reports Show Superbug Strains of Drug Resistant Gonorrhea on the Rise

LGM Pharma has forged partnerships with its clients to supply products for research and development needs.

BOCA RATON, Florida: Gonorrhea, a sexually transmitted disease (STD) caused by the bacterium *Neisseria Gonorrhoeae*, is a very common infectious disease among the sexually active young adults and teens. The Center for Disease Control and Prevention (CDC) estimates that more than 700,000 persons in the U.S. acquire the infection yearly. Unlike HIV, exchange of body fluids does not necessarily have to occur for the bacterium to get transmitted.

Six years ago, another group of antibiotics, fluoroquinolones, was crossed off the list of recommended drugs for the treatment of uncomplicated gonorrhea in Oregon and California due to widespread resistance to it. In the last decade, there have been a growing number of cases of gonorrhea that are resistant to Cefixime that is taken orally, and the injectable ceftriaxone.

These chilling reports have alerted LGM Pharma, a Boca Raton supplier of active pharmaceutical ingredients, and its partners to the gravity of the emerging "superbug" resistance. Rather than panic, the company and its clients have chosen to work closely together to combat the superbug. The unique partnerships forged by LGM Pharma with its clients currently in the forefront of antibiotic resistance research have put them in a pivotal position to supply tailored products for their research and development needs.

The disease is serious, and the propensity of some of its strains to be antibiotic resistant dooms the patient to a lifetime of incurable infection that spreads to other organs. The pharmaceutical industry, especially LGM Pharma, is taking action along with the medical community's fight against the superbug.

"The company is well aware of what's happening in the world of medical research and development," adds Mendy Schurder, COO of LGM Pharma. "These reports might seem inconsequential but these antibiotic resistant strains are of great concern and warrant significant attention and resources to make certain the necessary therapies are available when the need arises."

About LGM Pharma

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.